Table 4.

Clinical applications of cell-based therapies in radiation burns (BMSCs—bone-marrow mesenchymal stem cells; BMNCs—bone marrow mononuclear cells, ADSCs—adipose-derived stem cells; rh-bFGF—human recombinant fibroblast growth factor; vLPM —lyopreserved placental membrane containing viable cells).

Therapy	Compared To	Route and Number of Administrations	Burn Characteristics	Follow Up	# of Patients	Age Range	Result	Author	Year
autologous lipoaspirates containing ADSCs from a healthy donor site	NA	repeated low-invasive computer-assisted injection in supraclavicular region, the anterior chest wall	progressive lesions after radiation therapy	12, 18 and 31 months	20	37–71	progressive regeneration, including neovessel formation and improved hydration; systematic improvement or remission of symptoms	Rigotti G et al. [77]	2005
autologous BMSCs	NA	subcutaneous and intramuscular administrations	radiation burn	11 months	1	27	healing progression, significant therapeutic improvement	Lataillade et al. [75]	2007
autologous BMMNCs	NA	intradermal administrations	radiation burn	8 months	1	32	progression of the healing process, complete pain collapse	Bey et al. [73]	2010
autologous ADSCs, an angiogenic and mitogenic factor of rh-bFGF, and an artificial dermis	NA	intradermal injections and soaked with the artificial dermis	radiation burn	1.5 years	1	NA	healed wound; the regenerated tissue developed maturely in 1.5 years	Akita et al. [76]	2010
human cadaveric MSC	NA	instilled around and within the lesion	radiation-induced skin lesion	NA	1	66	reduction of the inflammation process, skin quality, and vasculature improvement	Portas et al. [74]	2016
vLPM	NA	allograft; 12 applications	radiation necrosis wound	3 months	1	73	wound closure in 98 days	Regulski et al. [12]	2019